Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ID 93

Next Previous
X
Search
Drug Profile

ID 93

Alternative Names: ID 93/AP10-602; ID-93/GLA-SE; ID93 + AP10-602; ID93 + GLA-SE; QTP-101; Tuberculosis vaccine adjuvanted - Aeras/Infectious Disease Research Institute; Tuberculosis vaccine recombinant Mycobacterium tuberculosis protein ID93/adjuvant GLA-SE - Aeras/IDRI; Tuberculosis-vaccine-ID93-Aeras/Infectious-Disease-Research-Institute; Tuberculosis-vaccine-recombinant-Mycobacterium-tuberculosis-protein-ID93-Aeras/IDRI

Latest Information Update: 10 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infectious Disease Research Institute
  • Developer Aeras; Infectious Disease Research Institute; National Institutes of Health; Quratis
  • Class Adjuvants; Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 03 Dec 2024 Quratis plans phase-I trial for Tuberculosis (Prevention, In adults, In the elderly) in South Korea (IM) in December 2024 (NCT06714513),
  • 01 Nov 2024 University of Oxford plans a clinical trial for Tuberculosis (Prevention) in the United Kingdom (IM, Injection) in November 2024 (NCT06670755)
  • 07 Mar 2023 ID 93 is still in phase I trials for Tuberculosis (Prevention)in USA (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top